Patents by Inventor Anastasia Khvorova

Anastasia Khvorova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20170349904
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for F12.
    Type: Application
    Filed: August 16, 2017
    Publication date: December 7, 2017
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Oligonucleotide compounds for targeting huntingtin mRNA
    Patent number: 9809817
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: November 7, 2017
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • BRANCHED OLIGONUCLEOTIDES
    Publication number: 20170312367
    Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.
    Type: Application
    Filed: January 30, 2017
    Publication date: November 2, 2017
    Inventors: Anastasia Khvorova, Matthew Hassler, Julia Alterman
  • Methods and compositions for selecting siRNA of improved functionality
    Patent number: 9777270
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: October 3, 2017
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • RNAi targeting ZNF205
    Patent number: 9771586
    Abstract: Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for ZNF205.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 26, 2017
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
    Patent number: 9745574
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: August 29, 2017
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
  • RNAi targeting SEC61G
    Patent number: 9719094
    Abstract: Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for SEC61G.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 1, 2017
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • RNAi targeting CNTD2
    Patent number: 9719092
    Abstract: Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for CNTD2.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 1, 2017
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • EXOSOMAL LOADING USING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES
    Publication number: 20170183686
    Abstract: In one aspect, the invention relates to a method of loading exosomes with oligonucleotide cargo, by incubating an oligonucleotide comprising one or more hydrophobic modifications with a population of exosomes for a period of time sufficient to allow loading of the exosomes with the oligonucleotide. Exosomes loaded with hydrophobic ally modified oligonucleotide cargo, and uses thereof, are also provided.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 29, 2017
    Inventors: Anastasia Khvorova, Neil Aronin, Marie Cecile Didiot
  • INHIBITION OF PCSK9 THROUGH RNAI
    Publication number: 20170137823
    Abstract: The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2?-O-methyl groups at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
    Type: Application
    Filed: October 6, 2016
    Publication date: May 18, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Joanne Kamens, Anastasia Khvorova
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20170067056
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: April 14, 2016
    Publication date: March 9, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY
    Publication number: 20170043024
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Application
    Filed: August 12, 2016
    Publication date: February 16, 2017
    Inventors: Anastasia Khvorova, Mehran Nikan, Matthew Hassler, Maire Osborn, Reka Haraszti, Andrew Coles, Anton Turanov, Neil Aronin
  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20170009239
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 12, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • RNAi Targeting CNTD2
    Publication number: 20160369278
    Abstract: Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for CNTD2.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • RNAi Targeting SEC61G
    Publication number: 20160369284
    Abstract: Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for SEC61G.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • RNAi Targeting ZNF205
    Publication number: 20160369276
    Abstract: Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for ZNF205.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
    Publication number: 20160355826
    Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
    Type: Application
    Filed: April 1, 2016
    Publication date: December 8, 2016
    Inventors: Anastasia Khvorova, Melissa Moore, Anton A. Turanov, Ananth Karumanchi
  • OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN mRNA
    Publication number: 20160355808
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Application
    Filed: April 1, 2016
    Publication date: December 8, 2016
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • Inhibition of PCSK9 through RNAi
    Patent number: 9493774
    Abstract: The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2?-O-methyl groups at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: November 15, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Joanne Kamens, Anastasia Khvorova
  • FULLY STABILIZED ASYMMETRIC SIRNA
    Publication number: 20160319278
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Application
    Filed: April 1, 2016
    Publication date: November 3, 2016
    Inventors: Anastasia Khvorova, Neil Aronin, Matthew Hassler, Julia Alterman